文献速递神经肿瘤神经重症

短程贝伐珠单抗治疗脑肿瘤放射性坏死的体积分析疗效

Efficacy of Short-Course Bevacizumab for Brain Tumor Radiation Necrosis with a Volumetric Analysis.
PubMed 文献 · World Neurosurg · 2026-05-15

回顾性分析11例磁共振确诊放射性坏死患者,接受2或3周期贝伐珠单抗(7.5 mg/kg 每3周)治疗。91%患者临床改善或稳定,激素使用从基线91%降至治疗结束36%;强化坏死体积、瘤周水肿及总病灶体积显著缩小,非强化坏死体积无显著变化。提示短程贝伐珠单抗可作为减少激素依赖的实用策略。

要点

  • 短程贝伐珠单抗(7.5 mg/kg 每3周,2–3周期)可显著缩小强化坏死和瘤周水肿体积。
  • 91%患者临床改善或稳定,激素使用从91%降至36%。
  • 非强化坏死体积无显著变化,治疗后部分体积反弹但多数维持临床获益。

核心结论

  • 短程贝伐珠单抗对脑肿瘤放射性坏死具有临床和影像学疗效,可作为减少激素使用的实用策略。

研究设计与样本

  • 回顾性分析11例磁共振确诊放射性坏死并接受2或3周期贝伐珠单抗(7.5 mg/kg 每3周)的患者。
  • 采用人工智能辅助体积分析(DeepBratumIA)在4个时间点量化病灶体积变化。

主要发现

  • 91%患者临床改善或稳定,激素使用从基线91%降至治疗结束36%。
  • 强化坏死中位体积从5.1 cm3降至1.2 cm3(P = 0.031)。
  • 非强化坏死体积从2.3 cm3降至2.0 cm3(P = 0.414),无显著变化。
  • 瘤周水肿体积从65 cm3降至18 cm3(P = 0.001),总病灶体积从69 cm3降至21 cm3(P = 0.001)。
  • 激素维持组与停用组在各时间点体积变化幅度无统计学显著差异。

关键数值与推荐

  • 贝伐珠单抗剂量为7.5 mg/kg 每3周,共2或3周期。
  • 临床结局采用东部肿瘤协作组体能状态和激素使用变化评估。

临床怎么用

  • 对于磁共振确诊的脑肿瘤放射性坏死,可考虑短程贝伐珠单抗以减轻激素负担并促进影像学改善。
  • 治疗期间需关注非强化坏死体积可能无显著变化及治疗后部分体积反弹。

局限性

  • 样本量小(11例),为回顾性分析。
  • 未设对照组,结论需更大样本前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Radiation necrosis (RN) is a challenging complication of cranial irradiation, often requiring corticosteroids for management. This study evaluates the clinical and radiologic efficacy of a short-course bevacizumab (BEV) regimen for brain tumor RN, with a volumetric assessment. METHODS: We retrospectively analyzed 11 patients with magnetic resonance imaging-confirmed RN who received 2 or 3 cycles of BEV (7.5 mg/kg every 3 weeks). Volume changes of nonenhancing RN, enhancing RN, perilesional edema, and total lesion (RN + edema) were quantified at 4 time points (pretreatment, start, end, and post-treatment) using artificial intelligence-assisted volumetric analysis (DeepBratumIA). Clinical outcomes were assessed using Eastern Cooperative Oncology Group performance status and changes in corticosteroid use. RESULTS: Clinical improvement or stabilization was observed in 91% of patients, with steroid use decreasing from 91% at baseline to 36% at treatment completion. Median enhancing RN volume significantly decreased from 5.1 cm3-1.2 cm3 (P = 0.031), while nonenhancing RN volume showed a nonsignificant change (2.3 cm3-2.0 cm3, P = 0.414). Perilesional edema volume markedly declined from 65 cm3-18 cm3 (P = 0.001), and total lesion volume decreased from 69 cm3-21 cm3 (P = 0.001). No statistically significant differences were observed between steroid-maintained and steroid-discontinued groups in the magnitude of volume change at any time point. Partial volumetric rebound occurred post-treatment, but most patients maintained clinical benefit. CONCLUSIONS: This study suggests the clinical and radiologic efficacy of short-course BEV as a practical steroid-sparing strategy for RN management.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ahn KH, Canisia Marcelina CD, Park JM, et al. Efficacy of Short-Course Bevacizumab for Brain Tumor Radiation Necrosis with a Volumetric Analysis. World Neurosurg. 2026. PMID: 42140313. doi:10.1016/j.wneu.2026.125043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。